225 related articles for article (PubMed ID: 16202823)
1. Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.
Seta T; Nagayama H; Katsura K; Hamamoto M; Araki T; Yokochi M; Utsumi K; Katayama Y
Clin Neurol Neurosurg; 2005 Oct; 107(6):491-6. PubMed ID: 16202823
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome.
Okamiya S; Ogino M; Ogino Y; Irie S; Kanazawa N; Saito T; Sakai F
Ther Apher Dial; 2004 Jun; 8(3):248-53. PubMed ID: 15154879
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.
Kaynar L; Altuntas F; Aydogdu I; Turgut B; Kocyigit I; Hacioglu SK; Ismailogullari S; Turgut N; Erkurt MA; Sari I; Oztekin M; Solmaz M; Eser B; Ersoy AO; Unal A; Cetin M
Transfus Apher Sci; 2008 Apr; 38(2):109-15. PubMed ID: 18331814
[TBL] [Abstract][Full Text] [Related]
4. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
[TBL] [Abstract][Full Text] [Related]
5. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption.
Marn Pernat A; Buturović-Ponikvar J; Svigelj V; Ponikvar R
Ther Apher Dial; 2009 Aug; 13(4):310-3. PubMed ID: 19695065
[TBL] [Abstract][Full Text] [Related]
6. Neuromuscular respiratory failure in Guillain-Barre Syndrome: evaluation of clinical and electrodiagnostic predictors.
Sundar U; Abraham E; Gharat A; Yeolekar ME; Trivedi T; Dwivedi N
J Assoc Physicians India; 2005 Sep; 53():764-8. PubMed ID: 16334619
[TBL] [Abstract][Full Text] [Related]
7. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
Dada MA; Kaplan AA
Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
[TBL] [Abstract][Full Text] [Related]
8. [Plasmapheresis in Guillain-Barre syndrome].
Carbajal-Ramírez A; Castañón-González JA; Osvaldo-Talavera J; de la Torre-Nieto ML; León-Gutiérrez MA
Gac Med Mex; 2002; 138(6):527-31. PubMed ID: 12532617
[TBL] [Abstract][Full Text] [Related]
9. Guillain-Barré syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.
França MC; Deus-Silva L; de Castro R; Garibaldi SG; Pfeilsticker BH; Nucci A; Marques JF
Arq Neuropsiquiatr; 2005 Sep; 63(3B):772-5. PubMed ID: 16258654
[TBL] [Abstract][Full Text] [Related]
10. [The effect of plasmapheresis and other immunomodulating therapies on the course of severe Guillain-Barré syndrome].
Hidasi E; Soltész P
Orv Hetil; 2001 Feb; 142(7):335-9. PubMed ID: 11243015
[TBL] [Abstract][Full Text] [Related]
11. Mechanical ventilation in Guillain-Barré syndrome: does age influence functional outcome?
Köhrmann M; Huttner HB; Nowe T; Schellinger PD; Schwab S
Eur Neurol; 2009; 61(6):358-63. PubMed ID: 19365128
[TBL] [Abstract][Full Text] [Related]
12. [Immunoadsorption therapy with TR-350 (tryptophan column) for Guillain-Barré syndrome: investigation including serum antiganglioside antibody assay].
Araki T; Nakata H; Kusunoki S; Arai Y; Katayama Y
Rinsho Shinkeigaku; 2000 Oct; 40(10):979-85. PubMed ID: 11296374
[TBL] [Abstract][Full Text] [Related]
13. The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome.
Sanjay R; Flanagan J; Sodano D; Gorson KC; Ropper AH; Weinstein R
J Clin Apher; 2006 Jul; 21(2):105-10. PubMed ID: 16342192
[TBL] [Abstract][Full Text] [Related]
14. Guillain-Barre syndrome: a clinical study in King Chulalongkorn Memorial Hospital.
Areeyapinan P; Phanthumchinda K
J Med Assoc Thai; 2010 Oct; 93(10):1150-5. PubMed ID: 20973317
[TBL] [Abstract][Full Text] [Related]
15. Clinical variants of Guillain-Barre syndrome: some aspects of differential diagnosis.
Dididze MN
Georgian Med News; 2009 Jan; (166):48-51. PubMed ID: 19202218
[TBL] [Abstract][Full Text] [Related]
16. Use of immunoglobulin in severe childhood Guillain-Barré syndrome.
Ortiz-Corredor F; Peña-Preciado M
Acta Neurol Scand; 2007 Apr; 115(4):289-93. PubMed ID: 17376129
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study of the efficacy of plasma exchange, immunoadsorption plasmapheresis and corticosteroid administration in the treatment of Guillain-Barré syndrome].
Yamazaki M; Koh CS; Hanyu N; Sakai T; Inoue A; Yanagisawa N
Arerugi; 1995 Apr; 44(4):498-502. PubMed ID: 7598643
[TBL] [Abstract][Full Text] [Related]
18. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS).
Verma R; Chaudhari TS; Raut TP; Garg RK
J Neurol Sci; 2013 Dec; 335(1-2):105-11. PubMed ID: 24064258
[TBL] [Abstract][Full Text] [Related]
19. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
Korinthenberg R; Schessl J; Kirschner J; Mönting JS
Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024
[TBL] [Abstract][Full Text] [Related]
20. Clinically diagnosed Guillain-Barre syndrome in Ile-Ife, Nigeria.
Sunmonu TA; Komolafe MA; Adewuya A; Olugbodi AA
West Afr J Med; 2008 Jul; 27(3):167-70. PubMed ID: 19256323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
